Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Regulatory press release

The subscription price for exercise of warrants of series TO6 in Lumito AB is set to SEK 0.39 and the subscription period commences today November 4, 2024

Lumito
Download the release

Lumito AB (publ) ("Lumito" or the "Company") issued warrants of series TO6 in connection to an issue and loan financing during the fourth quarter of 2023. Each warrant gives the right to subscribe for one (1) new share in the Company. The subscription price for the warrants has been set to 70 percent of the volume-weighted average price of the Company's share on NGM Nordic SME during the measurement period, which runs from and including October 21, 2024, to and including November 1, 2024, however not less than the quota value for the Company's shares and not more than SEK 1.40. The volume-weighted average price of the Company's share during the measurement period amounted to approximately SEK 0.55 and thus the subscription price has been set at SEK 0.39. The subscription period for the warrants runs during the period from and including November 4, 2024, to and including November 15, 2024.

Complete terms for the warrants are available on the Company’s website, www.lumito.se.

Summarized terms for the warrants of series TO6:
Exercise period: November 4, 2024 – November 15, 2024.

Subscription price: SEK 0.39 per share.

Issue volume: 34,406,248 warrants of series TO6 entitles to subscription of 34,406,248 shares. If all warrants are exercised the Company will receive approximately SEK 13.4 million before issuing costs.

Last day for trading with warrants: November 12, 2024.

Share capital and dilution: If all warrants of series TO6 are exercised the number of shares will increase with 34,406,248 shares from 233,691,423 shares to 268,097,671 shares and the share capital will increase with SEK 860,156.20, from SEK 5,842,285.58 to SEK 6,702,441.78, corresponding to a maximal dilution effect of 12.8 percent if the number of shares.

Note that the warrants that are not exercised at the latest November 15, 2024, or sold at the latest November 12, 2024, will expire without value. For the warrants of series TO6 not to lose their value, the holder must actively subscribe for new shares or sell the warrants. Please note that some nominees may close registration earlier than November 15, 2024.

How the warrants are exercised:
Nominee-registered warrants (custody account)

Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.

Direct-registered warrants (securities account)

No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.

Application form and instructions for subscription are available on the Company’s webpage, www.lumito.se.

Advisers
Mangold Fondkommission AB is financial adviser and Advokatfirman Lindahl KB is legal advisor to Lumito in connection with the exercise of the warrants of series TO6.

For further information, please contact:


Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Lumito


Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments
The subscription price for exercise of warrants of series TO6 in Lumito AB is set to SEK 0.39 and the subscription period commences today November 4, 2024

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.